For all press and media enquiries please contact mediarelations@chiesi.com
Thomas Eichholtz is the new Head of Global Research and Development at the Chiesi Group. A senior leader with over 25 years’ experience in Research and Development across the entire value chain, from target identification to registration and post-marketing activities, Thomas Eichholtz boasts a solid…
Deal provides Chiesi Group with worldwide, exclusive license to use Bioasis xB 3 TM platform for delivery of undisclosed enzymes in treatment of four lysosomal storage disorders. Under terms of the agreement, Bioasis will receive an upfront payment of US$3 million, additional potential milestone…
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic The Group commits €3 million for donations to support the ongoing emergency in Italy Sustained efforts designed to ensure continuity of supply-chain and…
Parma, January 30th 2020 – Chiesi Farmaceutici, an international research-focussed pharmaceutical group (Chiesi Group), has once again qualified for the title of Top Employer 2020 in Italy and Europe. Ten of the Group’s affiliates obtained the certification this year: Italy was awarded the title for…
Parma, 10 th January 2020 – Chiesi Farmaceutici, an international research-focussed pharmaceutical group (the Chiesi Group), announces it is set to take part in Parma Capital of Culture 2020. Key elements of Parma 2020 are promoting public-private partnerships and opening a dialogue among different…
Parma, December 18 th, 2019 – Chiesi Farmaceutici, an international research-focussed group (the Chiesi Group), announces it has been admitted to the Cooperative Compliance Programme set up by the Italian Revenue Agency (as provided by Legislative Decree 128/2015). Notification of its admission was…
Market leader in respiratory innovation highlights potentially harmful 1 consequences of short-term thinking in rush to introduce policies to switch patients to so-called ‘green inhalers’ as they announce breakthrough environmentally friendly pressurised metered dose inhaler (pMDI) ready by end of…
The Group is now one of the top 70 companies worldwide out of a total of 700. Out of the 300 Italian companies involved, Chiesi ranks 1 st among the 8 companies qualifying for the ranking. Parma, November 20 th 2019 – Chiesi Farmaceutici, a research-focused international pharmaceutical Group (the…
Data from two randomised, double-blind, parallel-group, active-controlled studies on the efficacy and safety of single-inhaler triple therapy in adult patients with uncontrolled asthma is published in The Lancet for the first time TRIMARAN and TRIGGER compared the single-inhaler triple therapy…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
